Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Observer-blinded, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women Between Gestational Age 14-34 Weeks and Non-Pregnant Women of 16-45 Years Old.

NCT05808166 is registered in ClinicalTrials.gov with International Vaccine Institute as lead sponsor.

NCT NCT05808166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05808166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Observer-blinded, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women Between Gestational Age 14-34 Weeks and Non-Pregnant Women of 16-45 Years Old.
Lead sponsor
International Vaccine Institute
Phase
Phase 2
Overall status
Recruiting
Start date
May 2, 2024
Completion date
April 30, 2026
Enrollment
2,358 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis e infection